Chapter 17 Rectal Cancer: Management of T1 Rectal Cancer

Woon Kyung Jeong and Jose G. Guillem

Introduction

The widespread implementation of screening colonoscopy has led to a parallel increase in the detection of early staged rectal cancer including T1N0M0 lesions. Rectal cancers at this stage have invaded into the submucosal layer of the rectal wall without metastasis to lymph nodes and other organs and have been traditionally managed with a transabdominal radical resection (RR). However, since a RR is associated with significant postoperative morbidity, local excisional approaches (LE) such as transanal excision (TAE), transanal endoscopic microsurgery (TEM), and transanal minimally invasive surgery (TAMIS), have been adopted. Whether the oncological results of a less morbid LE approach is comparable to a more morbid RR approach for T1N0M0 rectal cancer is the essential question of this chapter.

When confronted with a patient with a presumed T1N0M0 rectal cancer based on preoperative physical exam and imaging studies, both LE and RR options have to be considered and the pros and cons of each approach and their associated longterm and short-term oncological outcomes and functional consequences and implications for the specific patient at hand carefully discussed.

W.K. Jeong • J.G. Guillem (🖂)

Colorectal Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA e-mail: guillemj@MSKCC.ORG

[©] Springer International Publishing Switzerland 2017 N. Hyman, K. Umanskiy (eds.), *Difficult Decisions in Colorectal Surgery*, Difficult Decisions in Surgery: An Evidence-Based Approach, DOI 10.1007/978-3-319-40223-9_17

Search Strategy

P (patients)	I (intervention)	C (comparator)	O (outcomes)
Patients with T1 rectal	Local excision	Radical resection	Oncologic outcomes,
cancer			quality of life

A literature search in Pubmed, Embase, and Scopus databases was performed. The terms used for the search included: "T1 rectal cancer"; "early staged rectal cancer"; "local excision"; "radical resection"; "recurrence"; "sexual function"; "anorectal function" and "quality of life". Only articles written in English and published between 2010 and 2015 and reporting original data or meta-analysis on T1 rectal cancer were selected. Important and evidence-based studies published before 2010 were also included.

Results

We found two meta-analyses which met our search criteria and included most of the significant data on the topic (Table 17.1) [1, 2]. Of these two studies, one was larger (2896 patients from 13 studies [1] versus 860 patients from seven studies [2]) and reported detailed preoperative diagnostic workup and oncologic data including lymphovascular invasion and surgical margin status as well as the use of neoadjuvant and/or adjuvant therapy [1]. However, these two meta-analyses included studies that were retrospective and non-randomized [3–15], and some of the retrospective studies included small numbers of patients. The one prospective randomized study on this topic which was included in both meta-analyses only enrolled 50 patients [16].

Oncologic Outcomes

Local Recurrence

In our review of these two meta-analyses, rates of local recurrence were higher in patients undergoing a LE when compared to patients undergoing a RR (4-33% versus 0–6%, respectively) [1, 2].

Distant Metastasis

Of these two meta-analyses, only one compared distant metastasis rates between LE and RR and showed no significant differences (0-8% versus 0-4%, respectively) [2]. However, it is important to point out that this study included only patients undergoing TEM and did not include TAE or TAMIS.

	Study	Patients	Local	Distant					Quality of
fear	design	(LE/RR)	recurrence	metastasis	DFS	OS	Morbidity	Mortality	evidence
2015	Meta-	2896	LE>RR	n/a	5-years DFS,	5-years OS,	LE <rr< td=""><td>LE<rr< td=""><td>moderate</td></rr<></td></rr<>	LE <rr< td=""><td>moderate</td></rr<>	moderate
	analysis	(1315/1581)	(relative risk,		LE <rr< td=""><td>LE<rr< td=""><td>(relative</td><td>(relative</td><td></td></rr<></td></rr<>	LE <rr< td=""><td>(relative</td><td>(relative</td><td></td></rr<>	(relative	(relative	
			2.36; 95 %		(relative risk,	(relative risk,	risk, 0.20;	risk,	
			CI,		1.54; 95 % CI,	1.46; 95 % CI,	95 % CI,	0.31;	
			1.64 - 3.39		1.15 - 2.05)	1.19 - 1.77)	0.10 - 0.41)	95 % CI,	
								0.14 -	
								0.71)	
2015	Meta-	860	LE>RR(OR,	no difference	no	no	n/a	n/a	moderate
	analysis	(303/557)	4.62; 95 %	(OR, 0.74;	difference(OR,	difference(OR,			
			CI,	95 % CI,	1.12; 95 % CI,	0.87; 95 % CI,			
			2.03-10.53)	0.32 - 1.72)	0.31-4.12)	0.55 - 1.38)			
tion, <i>RR</i> nal mini	radical res imally invas	section, DFS dis sive surgery, CI,	sease-free surviv, confidence inter	al, OS, overall su rval, OR, overall r	irvival, TAE, trans isk, SEER, survei	sanal excision, <i>TE</i> llance, epidemiolo	<i>M</i> , transanal gy, and end r	endoscopic esults, HR h	microsurgery, azard risk
	(ear 2015 2015 2015 2015 2015 2015 2015 2015	Study design(015Meta-analysis015Meta-analysisanalysisanalysisanalysisanalysisanalysisanalysisanalysisanalysis	Study Patients (car design (LE/RR) (015 Meta- 2896 analysis (1315/1581) 015 Meta- 8860 015 Meta- 860 ontsile 860 1015 analysis (303/557) 1015 analysis (303/557) 1015	StudyPatientsLocaldesign(LE/RR)recurrence015Meta-2896LE>RRanalysis(1315/1581)(relative risk, 2.36; 95%015Meta-860LE>RR(OR, analysis015Meta-860LE>RR(OR, analysis015Meta-860LE>RR(OR, analysis016Meta-860LE>RR(OR, analysis017Meta-860LE>RR(OR, analysis018Meta-860LE>RR(OR, analysis1.64-3.39)	StudyPatientsLocalDistant $feardesign(LE/RR)recurrencemetastasis(015)Meta-2896LE>RRn/a(1315/1581)(relative risk,n/aanalysis(1315/1581)(relative risk,analysis(1315/1581)(relative risk,analysis(1315/1581)(relative risk,analysis(1315/1581)(relative risk,analysis(1315/1581)(relative risk,015Meta-860LE>RR(OR,ontsisis(303/557)4.62, 95\%00, 0.74;analysis(303/557)4.62; 95\%00, 0.74;ont, RR radical resection, DFS disease-free survival. OS, overall suontiminally invasive surgery, CI, confidence interval, OR, overall r$	StudyPatientsLocalDistantdesign(LE/RR)recurrencemetastasisDFS (215) Meta-2896LE>RR n/a 5-years DFS, (215) Meta-2896LE>RR n/a 5-years DFS, $(1315/1581)$ (relative risk, n/a 5-years DFS, $(1315/1581)$ (relative risk, $1.5 \times 95 \%$ (relative risk, $(1315/1581)$ $(relative risk,1.5 \times 95 \%(relative risk,(1315/1581)(relative risk,1.64-3.39)1.15-2.05)(15)Meta-860LE>RR(OR,no differenceno015Meta-860LE>RR(OR,no differenceno015Meta-860LE>RR(OR,0.74;difference(OR,analysis(303/557)4.62; 95 \%(OR, 0.74;1.12; 95 \% CI,on, RR radical resection, DFS disease-free survival, OS, overall survival, TAE, transnoOR, overall risk, SEER, surveiand minimally invasive surgery, CI, confidence interval, OR, overall risk, SEER, surveiOR voerall risk, SEER, survei$	Study fearPatients designLocal (LE/RR)Distant metastasisDFSOS015Meta-2896LE>RRm/a 5 -years DFS, telative risk, 5 -years OS, telative risk, 5 -years OS, telative risk, $1.315/1581$)015Meta-2896LE>RR n/a 5 -years DFS, telative risk, 5 -years OS, telative risk,015Meta-860LE>RR(OR, tot, 1.64-3.39) n/a 5 -years DFS, telative risk, 5 -years OS, telative risk,015Meta-860LE>RR(OR, tot, 1.64-3.39) n/a 5 -years OS, telative risk, $1.46; 95 \% CI,$ 1.19-1.77)015Meta-860LE>RR(OR, tot, 1.64-3.39) $n0$ $0.74;$ 0.74; $1.15-2.05$ $1.19-1.77$)016Meta-860LE>RR(OR, tot, $1.64-3.39$ $0.74;$ 1.15-2.05 $1.19-1.77$) 015 Meta-860LE>RR(OR, tot, $0.74;$ 0.74; $1.15-2.05$ $1.19-1.77$) 016 Meta-860LE>RR(OR, tot, $0.74;$ 0.32-1.72) $0.87; 95 \% CI,$ 0.357.95 $0.87; 95 \% CI,$ 016 Meta-860LE>RR(OR, 	Study fearPatients designLocal (LE/RR)Distant recurrenceDFSOSMorbidity(015Meta-2896LE>RR (1315/1581)LE <rr </rr (relative risk, 1.64-3.39)NaS-years DFS, 5-years DFS, 5-years DFS, 5-years OS,S-years OS, 1.64-3.39)LE <rr </rr (relative risk, 0.50, 1.54, 95 % CI, 1.15-2.05)LE <rr </rr 1.64-3.39)Norbidity015Meta-860LE>RR(OR, 0.60, 0.74; 0.10-0.41)1.15-2.05)1.19-1.77)0.10-0.41)015Meta-860LE>RR(OR, 0.60, 0.74; 0.33-57)No0.10-0.41)0.10-0.41)015Meta-860LE>RR(OR, 0.60, 0.74; 0.33-51)No0.10-0.41)0.10-0.41)016Meta-860LE>RR(OR, 0.74; 0.33-1.72)NoNo0.10-0.41)017Meta-860LE>RR(OR, 0.74; 0.31-4.12)NoNoNo016Meta-860LE>RR(OR, 0.32-1.72)NoNoNo017Meta-860LE>RR(OR, 0.31-4.12)NoNoNo016Meta-860LE>RR(OR, 0.31-4.12)NoNo017Meta-860LE>RR(OR, 0.32-1.72)NoNo018Meta-860LE>RR(OR, 0.31-4.12)NoNo017Meta-860LE>RR(OR, 0.31-4.12)NoNo018Meta-860LE>RR(OR, 0.33-1.72)NoNo018Meta-860LE>RR(OR, 0.30, 0.74;No </td <td>StudyPatientsLocalDistantDFSOSMorbidityMortality$(ear)$$(LE/RR)$recurrencemetastasisDFSOSMorbidityMortality$(015$Meta-2896$LE>RR$<math>LE<rr< math=""><math>LE<rr< math=""><math>LE<rr< math=""><math>LE<rr< math=""><math>LE<rr< math="">$(1315/1581)$(relative risk,1.5, 95% CI,1.6, 95% CI,95% CI,95% CI,$(1315/1581)$<math>(relative risk,1.54, 95% CI,1.46, 95% CI,95% CI,$(1315/1581)$$LE>RR$<math>(relative risk,<math>(relative risk,<math>(relative risk,<math>risk,$(1315/1581)$<math>(relative risk,1.54, 95% CI,1.46, 95% CI,95% CI,95% CI,$(1315/1581)$$Reta 860$<math>LE>RR(OR,$n00$$1.19-1.77$)$0.10-0.41$)$95\%$ CI,0.15Meta-860<math>LE>RR(OR,$n0$$0.71$)$0.19-1.77$)$0.10-0.41$)$95\%$ CI,0.15Meta-860<math>LE>RR(OR,$n0$$0.71$)$0.19-1.77$)$0.10-0.41$)$95\%$ CI,0.15Meta-860<math>LE>RR(OR,$n0$$0.71$)$0.19-1.77$)$0.10-0.41$)$95\%$ CI,$0.16$$0.71$$0.20-1.72$)$0.31-4.12$)$0.303/557$)$0.20-1.053$)$0.31-4.12$)$0.71$)$0.16$$0.71$$0.303/557$)$0.20-1.053$)$0.32-1.72$)$0.31-4.12$)$0.71$$0.16$$0.71$$0.71$$0.21-4.12$)$0.31-4.12$)$0.55\%$ CI,$0.71$$0.16$<</math></math></math></math></math></math></math></math></math></math></rr<></math></rr<></math></rr<></math></rr<></math></rr<></math></td>	StudyPatientsLocalDistantDFSOSMorbidityMortality (ear) (LE/RR) recurrencemetastasisDFSOSMorbidityMortality $(015$ Meta-2896 $LE>RR$ $LELELELELE(1315/1581)(relative risk,1.5, 95% CI,1.6, 95% CI,95\% CI,95\% CI,(1315/1581)(relative risk,1.54, 95% CI,1.46, 95% CI,95\% CI,(1315/1581)LE>RR(relative risk,(relative risk,(relative risk,risk,(1315/1581)(relative risk,1.54, 95% CI,1.46, 95% CI,95\% CI,95\% CI,(1315/1581)Reta 860LE>RR(OR,n001.19-1.77)0.10-0.41)95\% CI,0.15Meta-860LE>RR(OR,n00.71)0.19-1.77)0.10-0.41)95\% CI,0.15Meta-860LE>RR(OR,n00.71)0.19-1.77)0.10-0.41)95\% CI,0.15Meta-860LE>RR(OR,n00.71)0.19-1.77)0.10-0.41)95\% CI,0.160.710.20-1.72)0.31-4.12)0.303/557)0.20-1.053)0.31-4.12)0.71)0.160.710.303/557)0.20-1.053)0.32-1.72)0.31-4.12)0.710.160.710.710.21-4.12)0.31-4.12)0.55\% CI,0.710.16<$

cancer
rectal
Ξ
on
studies
SIS
meta-analy
of
parison
Com
le 17.1
le

Overall Outcome

In one meta-analysis, disease-free survival rate was higher in patients undergoing a RR [1]. However, in the other meta-analysis, no significant difference was noted in disease-free survival between the two surgical treatment options [2]. This may be due to the fact that in the latter met-analysis, only 2 studies reporting disease-free survival were included.

With regard to overall survival, one meta-analysis showed better results for RR over LE [1]. The other meta-analysis did not, even though it did demonstrate a significantly higher local recurrence rate in patients undergoing a LE (odds ratio, 4.62; 95% confidence interval, 2.03–10.53) [2]. The authors do not provide an explanation for this. However, it is possible that salvage radical surgery and adjuvant chemotherapy and/or radiation therapy may have eradicated some of the locally recurrent rectal cancer and impacted survival in a positive manner. However, other studies suggest that failure following a local excision may not be salvageable in a significant number of cases [17].

Quality of Life

Of the two meta-analyses, only one reported on morbidity and noted a higher morbidity rate for RR over LE [1]. LE was associated with a much lower need for permanent stoma [1]. However, a number of the studies included were from over 20 years ago when sphincter sparing TME was not as established as it is today.

There is a paucity of literature comparing sexual or anorectal functions following RR and LE and none are prospective randomized studies. Therefore, the two metaanalyses [1, 2] did not discuss this topic. One study not included in the two metaanalysis, however, did compare the quality of life after TEM and TME in sex- and age-matched patients and reported no significant differences in quality of life between TEM and TME; but more frequent defecation disorders were observed after TME [18]. A trend toward better sexual function after TEM was also reported. However, a greater portion of patients in the TME group were T3 and received preoperative radiotherapy (18% versus 0%) which probably had a negative impact on sexual function.

Other Studies

There are several recently published papers comparing local excision to radical resection that were not included in our analyses for specific reasons. One study included T1 and T2 rectal cancers and did not provide a subset analysis on T1 cancers [19] and the other included endoscopic polypectomy in the LE group [20]. One single institution study comparing LE to RR was not included in either of the metaanalyses [21]. It was a small sample (n=124), retrospective study which demonstrated a local recurrence rate of 11% in the LE group versus 1.6% in the RR group, but no difference in the disease-free and overall survival between the two groups. Our institutional experience at Memorial Sloan-Kettering Cancer Center (MSKCC) on a larger cohort (n=282) with a similar length of follow-up demonstrated an inferior disease-specific survival for patients with a T1 rectal cancer undergoing a LE relative to those undergoing a RR (87% versus 96%) [12].

In summary, the best available data suggest that a RR offers an oncologic advantage over a LE approach for early staged (T1N0M0) rectal cancer. This is probably related to the increased likelihood of a local recurrence noted after a LE approach, which is not always salvageable.

Evidence Based Recommendations

A review of the published oncological results demonstrates that a RR provides the best oncologic outcome for a T1 rectal cancer. LE is an option for patients with T1 rectal cancer without high risk features who either are not suitable for a RR or are willing to accept the oncological risks in the interest of avoiding the functional consequences of a RR. There should not be enlarged mesorectal lymph nodes suspicious for metastasis on preoperative images nor evidence of poor differentiation (PD), lymphovascular invasion (LVI), perineural invasion (PNI), or submucosal (Sm) invasion >1 mm on pathological analysis. If one of these high risk features in noted, a RR is recommended [22, 23]. If such a patient were to insist on having a LE rather than the recommended RR, they have to understand that local recurrence rates after LE of a T1 rectal cancer range between 12 and 29% with long-term follow-up, despite applying careful selection criteria for LE [5, 10, 15, 24, 25]. If a local recurrence develops and a salvage surgery is pursued, it would likely be extensive as one study reported the need for multivisceral pelvic resection in 33% and total pelvic exenteration in 5% of patients undergoing a RR after a recurrence following a LE of T1 rectal cancer [17].

- 1. Patients with a T1N0M0 rectal cancer that are otherwise fit should be offered a radical resection incorporating mesorectal excision.
- Patients with a T1N0M0 rectal cancer not able to undergo a radical resection may be offered a local excision understanding the increased risk for failure with possible limited salvage options.

Grade of data: moderate quality

A Personal View/Approach

If a patient is found to have a biopsy proven rectal adenocarcinoma that clinically looks and feels like it is not deeply invasive (mobile, non tethered, exophytic rather than ulcerated) and possibly amenable to a LE, a careful review of the pathology as well as local [endorectal ultrasonography (ERUS) or rectal magnetic resonance imaging (MRI)] and distant [computed tomography (CT) of chest, abdomen and pelvis] staging has to occur in order to further determine if indeed a LE approach is appropriate. The presence of any adverse pathological features (PD, LVI, PNI, or Sm invasion >1 mm) would be associated with an increased likelihood of mesorectal lymph node involvement and in an otherwise healthy individual with good anorectal sphincter function (good baseline tonicity, squeeze, no paradoxical motion of puborectalis sling, etc.), a RR would be offered. In an elderly individual with significant co-morbidities and/or poor anorectal function, a LE approach would be a safer initial approach (lower morbidity, mortality, and probable better function) than a RR but would be associated with a possible increased risk of local and distant failure. A more challenging scenario is the otherwise healthy individual with a very distal (1 cm above upper part of anorectal sphincter) invasive (T1N0M0 on imaging) rectal adenocarcinoma with good pathological features who is interested in a restorative curative resection. In this situation, the patient has to be informed that if LE is pursued initially and pathology identifies a T2 lesion and he/she were to pursue a subsequent salvage RR, this may or may not be feasible since the prior suture line fibrosis of LE would compromise creation of coloanal anastomosis and function.

Numerous other clinical scenarios exist based upon the local and distant staging of the rectal cancer, the presence or absence of poor pathological features, the distalmost location of the lesion relative to the upper most portion of the anorectal sphincters, the function of the anorectal sphincters, the presence or absence of co-morbidities, etc. Optimal matching of the treatment plan to the individual patient requires that all the above variables be taken into consideration and that the patient and family be informed and engaged in a discussion where short and long term wishes, risks, gains and losses are clearly discussed and agreed upon.

References

- Kidane B, Chadi SA, Kanters S, et al. Local resection compared with radical resection in the treatment of T1N0M0 rectal adenocarcinoma: a systematic review and meta-analysis. Dis Colon Rectum. 2015;58(1):122–40.
- Lu JY, Lin GL, Qiu HZ, et al. Comparison of transanal endoscopic microsurgery and total mesorectal excision in the treatment of T1 rectal cancer: a meta-analysis. PLoS One. 2015;10(10), e0141427.
- Heintz A, Morschel M, Junginger T. Comparison of results after transanal endoscopic microsurgery and radical resection for T1 carcinoma of the rectum. Surg Endosc. 1998;12(9):1145–8.
- Ambacher T, Kasperk R, Schumpelick V. Effect of transanal excision on rate of recurrence of stage I rectal carcinoma in comparison with radical resection methods. Chirurg. 1999; 70(12):1469–74.
- 5. Mellgren A, Sirivongs P, Rothenberger DA, et al. Is local excision adequate therapy for early rectal cancer? Dis Colon Rectum. 2000;43(8):1064–71; discussion 1071–4.
- 6. Lee W, Lee D, Choi S, et al. Transanal endoscopic microsurgery and radical surgery for T1 and T2 rectal cancer. Surg Endosc. 2003;17(8):1283–7.

17 Rectal Cancer: Management of T1 Rectal Cancer

- Langer C, Liersch T, Süss M, et al. Surgical cure for early rectal carcinoma and large adenoma: transanal endoscopic microsurgery (using ultrasound or electrosurgery) compared to conventional local and radical resection. Int J Colorectal Dis. 2003;18(3):222–9.
- 8. Nascimbeni R, Nivatvongs S, Larson DR, et al. Long-term survival after local excision for T1 carcinoma of the rectum. Dis Colon Rectum. 2004;47(11):1773–9.
- 9. Endreseth BH, Myrvold HE, Romundstad P, et al. Transanal excision vs. major surgery for T1 rectal cancer. Dis Colon Rectum. 2005;48(7):1380–8.
- You YN, Baxter NN, Stewart A, et al. Is the increasing rate of local excision for stage I rectal cancer in the United States justified?: a nationwide cohort study from the National Cancer Database. Ann Surg. 2007;245(5):726–33.
- Tarantino I, Hetzer FH, Warschkow R, et al. Local excision and endoscopic posterior mesorectal resection versus low anterior resection in T1 rectal cancer. Br J Surg. 2008;95(3):375–80.
- Nash GM, Weiser MR, Guillem JG, et al. Long-term survival after transanal excision of T1 rectal cancer. Dis Colon Rectum. 2009;52(4):577–82.
- Palma P, Horisberger K, Joos A, et al. Local excision of early rectal cancer: is transanal endoscopic microsurgery an alternative to radical surgery? Rev Esp Enferm Dig. 2009;101(3): 172–8.
- Ptok H, Marusch F, Meyer F, et al. Oncological outcome of local vs radical resection of lowrisk pT1 rectal cancer. Arch Surg. 2007;142(7):649–55; discussion 656.
- De Graaf EJ, Doornebosch PG, Tollenaar RA, et al. Transanal endoscopic microsurgery versus total mesorectal excision of T1 rectal adenocarcinomas with curative intention. Eur J Surg Oncol. 2009;35(12):1280–5.
- 16. Winde G, Nottberg H, Keller R, et al. Surgical cure for early rectal carcinomas (T1). Transanal endoscopic microsurgery vs. anterior resection. Dis Colon Rectum. 1996;39(9):969–76.
- 17. You YN, Roses RE, Chang GJ, et al. Multimodality salvage of recurrent disease after local excision for rectal cancer. Dis Colon Rectum. 2012;55(12):1213–9.
- Doornebosch PG, Tollenaar RA, Gosselink MP, et al. Quality of life after transanal endoscopic microsurgery and total mesorectal excision in early rectal cancer. Colorectal Dis. 2007; 9(6):553–8.
- 19. Sajid MS, Farag S, Leung P, et al. Systematic review and meta-analysis of published trials comparing the effectiveness of transanal endoscopic microsurgery and radical resection in the management of early rectal cancer. Colorectal Dis. 2014;16(1):2–14.
- Bhangu A, Brown G, Nicholls RJ, et al. Survival outcome of local excision versus radical resection of colon or rectal carcinoma a surveillance, epidemiology, and end results (SEER) population-based study. Ann Surg. 2013;258(4):563–9.
- 21. Peng J, Chen W, Sheng W, et al. Oncological outcome of T1 rectal cancer undergoing standard resection and local excision. Colorectal Dis. 2011;13(2):e14–9.
- Beaton C, Twine CP, Williams GL, et al. Systematic review and meta-analysis of histopathological factors influencing the risk of lymph node metastasis in early colorectal cancer. Colorectal Dis. 2013;15(7):788–97.
- Huh JW, Kim HR, Kim YJ. Lymphovascular or perineural invasion may predict lymph node metastasis in patients with T1 and T2 colorectal cancer. J Gastrointest Surg. 2010; 14(7):1074–80.
- Paty PB, Nash GM, Baron P, et al. Long-term results of local excision for rectal cancer. Ann Surg. 2002;236(4):522–9; discussion 529–30.
- 25. Madbouly KM, Remzi FH, Erkek BA, et al. Recurrence after transanal excision of T1 rectal cancer: should we be concerned? Dis Colon Rectum. 2005;48(4):711–9; discussion 719–21.